Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P450

Add time:09/06/2019    Source:sciencedirect.com

Incubation of [14C]tianeptine (0.5 mM) with human liver microsomes and a NADPH-generating system resulted in the in vitro covalent binding of a tianeptine metabolite to microsomal proteins. This covalent binding required oxygen and NADPH. It was decreased by piperonyl butoxide (4mM) by 81%, and SKF 525-A (4mM) by 87%, two relatively non-specific inhibitors of cytochrome P450, and by glutathione (4mM) by 70%, a nucleophile. Covalent binding was decreased by 54% in the presence of troleandomycin (0.1 mM), a specific inhibitor of the glucocorticoid-inducible cytochrome P450 IIIA3, but remained unchanged in the presence of quinidine (0.1 mM) or dextromethorphan (0.1 mM), two inhibitors of cytochrome P450 IID6. Preincubation with IgG antibodies directed against cytochrome P450 IIIA3 decreased covalent binding by 65% whereas either preimmune IgG or IgG antibodies directed against P450 IA1, an isoenzyme inducible by polycyclic aromatic compounds, exhibited no significant inhibitory effect. We conclude that tianeptine is activated by human liver cytochrome P450 into a reactive metabolite. This activation is mediated in part by glucocorticoidinducible isoenzymes but not by P450 IID6 (the isoenzyme which oxidizes debrisoquine) nor by P450 IA1 (an isoenzyme inducible by polycyclic aromatic compounds). The predictive value of this study regarding possible idiosyncratic and immunoallergic reactions in humans remains unknown.

We also recommend Trading Suppliers and Manufacturers of tianeptine MC(5) (cas 104732-22-1). Pls Click Website Link as below: cas 104732-22-1 suppliers

Prev:Increased serotonin platelet uptake after tianeptine administration in depressed patients
Next:Metabolic activation of the antidepressant tianeptine: II. in vivo covalent binding and toxicological studies at sublethal doses)